Global Information
회사소개 | 문의 | 비교리스트

폭식 장애 : 파이프라인 리뷰

Binge Eating Disorder - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 283206
페이지 정보 영문 62 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


폭식 장애 : 파이프라인 리뷰 Binge Eating Disorder - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 62 Pages

폭식 장애는 주체할 수 없는 음식물 섭취와 그로 인한 체중 증가로 특징지을 수 있는 싱각한 상태입니다. 폭식 장애의 원인은 밝혀지지 않았습니다. 그러나 가족력, 생물학적 요소, 장기적인 다이어트와 심리적 문제가 위험을 높입니다. 증후와 증상에는 비정상적으로 많은 양의 식사 섭취, 혼자서 자주 하는 식사, 섭취 행동을 통제할 수 없다고 느끼는 것, 우울감과 불안감 등이 있습니다. 치료법에는 심리치료, 약물치료와 행동치료, 체중 감소 프로그램 등이 있습니다.

세계의 폭식 장애(Binge Eating Disorder) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 각 임상 단계별 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

폭식 장애 개요

치료제 개발

  • 파이프라인 제품 개요

폭식 장애 : 기업에서 개발중인 치료제

폭식 장애 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

폭식 장애 : 기업에서 개발중인 제품

폭식 장애 치료제 개발에 참여하고 있는 기업

  • Heptares Therapeutics Limited
  • Omeros Corporation
  • Opiant Pharmaceuticals, Inc.
  • Polleo Pharma Limited
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

폭식 장애 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

폭식 장애 : 최근의 파이프라인 동향

폭식 장애 : 휴지중인 프로젝트

폭식 장애 : 개발이 중지된 제품

폭식 장애 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Binge Eating Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, H1 2020
  • Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H1 2020
  • Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Binge Eating Disorder - Pipeline by Omeros Corp, H1 2020
  • Binge Eating Disorder - Pipeline by OXonium Therapeutics, H1 2020
  • Binge Eating Disorder - Pipeline by Seropeutics LLC, H1 2020
  • Binge Eating Disorder - Pipeline by Sosei Heptares, H1 2020
  • Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
  • Binge Eating Disorder - Pipeline by Vivus Inc, H1 2020
  • Binge Eating Disorder - Dormant Projects, H1 2020
  • Binge Eating Disorder - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Binge Eating Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Binge Eating Disorder - Overview
    • Binge Eating Disorder - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Binge Eating Disorder - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Binge Eating Disorder - Companies Involved in Therapeutics Development
    • Amygdala Neurosciences Inc
    • Chronos Therapeutics Ltd
    • F. Hoffmann-La Roche Ltd
    • Omeros Corp
    • Oxonium Therapeutics
    • Seropeutics LLC
    • Sosei Heptares
    • Sunovion Pharmaceuticals Inc
    • Vivus Inc
  • Binge Eating Disorder - Drug Profiles
    • (phentermine hydrochloride + topiramate) ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANS-6637 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-010018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasotraline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5256390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SERx-480 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Binge Eating Disorder - Dormant Projects
  • Binge Eating Disorder - Discontinued Products
  • Binge Eating Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Nov 20, 2019: New Clinical data demonstrate VIVUS' Qsymia is effective at reducing Binge Eating in patients with Binge-Eating Disorder or Bulimia Nervosa
      • Jul 30, 2019: Sunovion announces acceptance by the U.S. FDA of the new drug application for Dasotraline for the treatment of adults with moderate-to-severe binge eating disorder
      • May 02, 2019: Sunovion to present data on dasotraline at the 2019 American Psychiatric Association Annual Meeting
      • Jul 25, 2018: Sunovion announces positive top-line results from pivotal study evaluating Dasotraline in adults with binge eating disorder
      • May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
      • May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting
      • Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress
      • Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
      • May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
      • May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase
      • Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
      • Oct 06, 2016: Study Finds New Approach to Block Binge Eating
      • Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q